MARKET

LXRX

LXRX

Lexicon Pharmaceuticals Inc
NASDAQ
1.880
-0.020
-1.05%
Closed 17:59 09/29 EDT
OPEN
1.920
PREV CLOSE
1.900
HIGH
1.940
LOW
1.800
VOLUME
3.95M
TURNOVER
0
52 WEEK HIGH
2.680
52 WEEK LOW
1.100
MARKET CAP
836.52M
P/E (TTM)
-12.2876
1D
5D
1M
3M
1Y
5Y
1D
Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy
Seeking Alpha · 1d ago
Midday Fly By: Nvidia boosts buyback, Boeing discovers 737 Max glitch
TipRanks · 1d ago
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Benzinga · 1d ago
Lexicon Pharma Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 1d ago
Lexicon Pharma Price Target Announced at $8.00/Share by Cantor Fitzgerald
Dow Jones · 1d ago
Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8
Benzinga · 1d ago
Lexicon initiated with an Overweight at Cantor Fitzgerald
TipRanks · 1d ago
Weekly Report: what happened at LXRX last week (0921-0925)?
Weekly Report · 2d ago
More
About LXRX
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.

Webull offers Lexicon Pharmaceuticals Inc stock information, including NASDAQ: LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.